Heather White, MD
Hematology & Oncology · Greenville, NCNPI 1730182965
Payments from drug & device makers
Across 90 payments — averaging $33.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$816
- Roche Diagnostics International Ltd$800
- Pfizer$160
- Sanofi$146
- Novartis$133
- Merck$131
- plus $825 from 21 others
What the payments were for
- Speaking & faculty fees$80027%
- Food & beverage$1,29943%
- Education$91330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 9 | $816 |
| Roche Diagnostics International Ltd | 1 | $800 |
| Pfizer | 11 | $160 |
| Sanofi | 2 | $146 |
| Novartis | 8 | $133 |
| Merck | 9 | $131 |
| E.r. Squibb & Sons, L.L.C. | 10 | $122 |
| Johnson & Johnson(2 entities) | 7 | $120 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $85 |
| Genentech USA, Inc. | 5 | $75 |
| AstraZeneca(2 entities) | 4 | $67 |
| Eisai Inc. | 3 | $48 |
| Boehringer Ingelheim | 2 | $28 |
| Amgen | 2 | $27 |
| Gilead(2 entities) | 2 | $26 |
| Coherus Oncology, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 2 | $24 |
| Tesaro, Inc. | 1 | $22 |
| Exelixis Inc. | 2 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- cobas EBV$800
- SARCLISA$125
How this compares
$3,012 in reported general payments places this provider in the 40th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 53 | $823,788 |
| VerzenioAbemaciclib | 30 | $455,713 |
| AyvakitAvapritinib | 11 | $402,526 |
| TrazimeraTrastuzumab-Qyyp | 99 | $374,545 |
| RevlimidLenalidomide | 18 | $350,879 |
| LynparzaOlaparib | 12 | $232,024 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $201,287 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 23 | $73,497 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $40,682 |
| EliquisApixaban | 38 | $31,642 |
| XareltoRivaroxaban | 42 | $26,167 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $24,956 |
| Xtampza ErOxycodone Myristate | 11 | $10,953 |
| Anastrozole | 637 | $10,715 |
| FemaraLetrozole | 12 | $8,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Trazimera, Octagam, Eliquis | $160 | $1,270,657206 claims |
| Lilly USA, LLCVerzenio | $816 | $455,71330 claims |
| Bristol Myers SquibbRevlimid | $20 | $350,87918 claims |
| AstraZenecaLynparza | $67 | $232,02412 claims |
| Johnson & JohnsonXarelto | $120 | $26,16742 claims |
| NovartisFemara | $133 | $8,96812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Greenville
- Darla LilesGreenville$4.8M
- Raid AljumailyGreenville$4.6M
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.